Abstract
The endocannabinoid system has long been known as a modulator of several physiological functions, among which the homeostatic and hedonic aspects of eating. CB1 receptors are widely expressed in brain regions that control food intake, reward and energy balance. Animal and human studies indicate that CB1 receptor agonists possess orexigenic effects enhancing appetite and increasing the rewarding value of food. Conversely, CB1 antagonists have been shown to inhibit the intake of food.
Eating disorders include a range of chronic and disabling related pathological illnesses that are characterized by aberrant patterns of feeding behaviour and weight regulation, and by abnormal attitudes and perceptions toward body shape image. The psychological and biological factors underlying eating disorders are complex and not yet completely understood. However in the last decades, converging evidence have led to hypothesise a link between defects in the endocannabinoid system and eating disorders, including obesity. Here we review the neurochemical and behavioural preclinical evidence supporting the role of the endocannabinoid system in eating disorders to offer the reader an update regarding the state of the art. Despite the recent withdrawal from the market of rimonabant for treating obesity and overweight individuals with metabolic complications due to its psychiatric side effects, preclinical findings support the rationale for the clinical development of drug which modulate the endocannabinoid system in the treatment of eating disorders.
Keywords: Endocannabinoid system, CB1 receptors, food intake, eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, obesity.
Current Pharmaceutical Design
Title:The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Volume: 20 Issue: 13
Author(s): Maria Scherma, Liana Fattore, Maria Paola Castelli, Walter Fratta and Paola Fadda
Affiliation:
Keywords: Endocannabinoid system, CB1 receptors, food intake, eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, obesity.
Abstract: The endocannabinoid system has long been known as a modulator of several physiological functions, among which the homeostatic and hedonic aspects of eating. CB1 receptors are widely expressed in brain regions that control food intake, reward and energy balance. Animal and human studies indicate that CB1 receptor agonists possess orexigenic effects enhancing appetite and increasing the rewarding value of food. Conversely, CB1 antagonists have been shown to inhibit the intake of food.
Eating disorders include a range of chronic and disabling related pathological illnesses that are characterized by aberrant patterns of feeding behaviour and weight regulation, and by abnormal attitudes and perceptions toward body shape image. The psychological and biological factors underlying eating disorders are complex and not yet completely understood. However in the last decades, converging evidence have led to hypothesise a link between defects in the endocannabinoid system and eating disorders, including obesity. Here we review the neurochemical and behavioural preclinical evidence supporting the role of the endocannabinoid system in eating disorders to offer the reader an update regarding the state of the art. Despite the recent withdrawal from the market of rimonabant for treating obesity and overweight individuals with metabolic complications due to its psychiatric side effects, preclinical findings support the rationale for the clinical development of drug which modulate the endocannabinoid system in the treatment of eating disorders.
Export Options
About this article
Cite this article as:
Scherma Maria, Fattore Liana, Castelli Paola Maria, Fratta Walter and Fadda Paola, The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence, Current Pharmaceutical Design 2014; 20 (13) . https://dx.doi.org/10.2174/13816128113199990429
DOI https://dx.doi.org/10.2174/13816128113199990429 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Mitochondrial Complex I Deficiency in Humans
Current Genomics Neuroactive Molecules in the Brains of Nonhuman Primates and Their Therapeutic Application to Neurodegenerative Disorders
Central Nervous System Agents in Medicinal Chemistry Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design The Prospect for Type 2 Diabetes Mellitus Combined with Exercise and Synbiotics: A Perspective
Current Diabetes Reviews Aldose Reductase: A Novel Target for Cardioprotective Interventions
Current Drug Targets Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design Pantothenate Kinase-Associated Neurodegeneration
Current Drug Targets Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design 11 Years of Cyanopyrrolidines as DPP-IV Inhibitors
Current Topics in Medicinal Chemistry Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry